M

Michael R. Loebinger

Royal Brompton & Harefield NHS Foundation Trust

ORCID: 0000-0002-5965-9913

357 papers and 13.7k citations.

PubIndex Score97Top 3%How it's scored

357Publications

13.7kTotal Citations

First senior author: 2012

Top publicationsby citations

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study

David E. Griffith, Kevin Winthrop, Gina Eagle et al.|American Journal of Respiratory and Critical Care Medicine|2018

Cited by 343

Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry

Raja Dhar, Nayan Sri Gulecha, P A Mahesh et al.|European Respiratory Journal|2022

Cited by 97

A Bispecific Monoclonal Antibody Targeting Psl and PcrV for Chronic Pseudomonas Aeruginosa Infection in Patients With Bronchiectasis: Results From a Randomized, Double-Blind Placebo-Controlled Trial (GREAT-2)

M.B. Long, James D. Chalmers, Rebecca C Hull et al.|American Journal of Respiratory and Critical Care Medicine|2025

Cited by 8

Proteinase 3 as a marker of clinical severity in bronchiectasis: Data from the EMBARC-BRIDGE study

Emma Johnson, James D. Chalmers, Megan Crichton et al.|Unknown|2023

Cited by 2

Airway CD10/neprilysin is related to lung function and disease severity in patients with bronchiectasis: Preliminary data from the EMBARC BRIDGE study

Hannah Dickson, James D. Chalmers, Rebecca C Hull et al.|Unknown|2025

Cited by 0

Indexing the rest of 357 publications…